Upperton Pharma Solutions, a contract development and manufacturing organization (CDMO), reported a £5 million investment to expand operations into small-scale sterile fill-finish.

After completion of a new 50,000 sq.-ft. GMP facility in 2023, the UK-based company will expand its Trent Gateway site to include sterile capabilities with a purpose-built facility designed specifically in line with the revised EU GMP Annex-1 regulations.

Construction of the facility will begin this February and is expected to be completed in early 4Q24.

The investment into an additional 7,000 sq.-ft. sterile manufacturing facility at Trent Gateway, follows significant growth in demand for the formulation development and manufacture of sterile and terminally sterilized products.

The sterile facility will use advanced VHP isolation technology and carry out GMP fill-finish of sterile drug products for biologics and small molecules, making use of existing full-service formulation development and quality control labs. The facility will support the manufacturing of aseptic and terminally sterilized small volume liquids for parenteral, ocular, and pulmonary delivery.

Nikki Whitfield, CEO of Upperton Pharma Solutions said, “This investment addresses a real shortage within our industry of providers of small batches of sterile drug products to support early clinical trials. Given our existing formulation development and analytical capabilities, it represents a natural progression for Upperton and an exciting milestone in our growth plans.”